CVS Generic Drugs Suit Fails to Get Class Action California judge blocks 11 classes in suit that claims CVS charged insurers and insured patients more than uninsured patients. CVS Health Names New COO March 08, 2017 By Christine Blank Jonathan C. Roberts is named Executive Vice President and COO. Walmart Pharmacy Adds Express Lanes to Its App March 02, 2017 By Christine Blank New express lanes are designed to make it easier for customers to quickly fill their prescriptions. Rite Aid, Albertsons Expand Naloxone Access February 28, 2017 By Christine Blank Rite Aid and Albertsons expand naloxone Access, hoping to curb the opioid epidemic. Report: Pharmacists dispensing dangerous drug combos January 09, 2017 By Christine Blank Walgreens, CVS Health and other drug chains promised to improve procedures after a Chicago Tribune investigation found that pharmacists at several retail chains filled prescriptions with dangerous drug combinations. Analyst: CVS’ OptumRx deal amps up competition December 06, 2016 By Christine Blank Last month, OptumRx and CVS Pharmacy announced that they are partnering to provide more convenient choices and lower costs for patients. Omnicare to pay $28 million for kickback scheme October 21, 2016 By Christine Blank Omnicare agreed to settle claims that it conspired with Abbott Laboratories “to engage in a number of disguised kickback arrangements to increase overall use of Depakote,” Some customers say CVS pill bottles miss the target September 30, 2016 By Christine Blank Some customers are upset over CVS Pharmacy’s switch to different pill bottles than the ones Target has used for more than a decade. CVS pharmacists must check PMP before dispensing opioids September 11, 2016 By Christine Blank The agreement between CVS and Massachusetts requiring the PMP check prior to dispensing opioids is believed to be the first in the nation. PBM giants cut drug expenses September 10, 2016 By Christine Blank When Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.